Enteric fever, commonly known as typhoid fever, is a systemic infection caused by Salmonella Typhi or Paratyphi. Despite advancements in diagnostic methods and treatment, it remains a significant global health issue, particularly in low-resource settings. This article aims to provide a comprehensive guide for healthcare professionals to optimize diagnosis and treatment strategies for enteric fever.
Diagnosing enteric fever can be challenging due to its nonspecific symptoms and the limitations of current diagnostic tests. Blood culture, the gold standard for diagnosis, has a sensitivity of only 40-60%. There is a pressing need for improved diagnostic tools that are both accurate and practical for use in resource-limited settings.
Recent advancements have led to the development of rapid diagnostic tests (RDTs), which offer promising results. These tests, based on the detection of specific antigens or antibodies, provide results within hours. However, more research is needed to establish their reliability and cost-effectiveness.
The mainstay of treatment for enteric fever is antibiotic therapy. However, the emergence of multi-drug resistant (MDR) strains has complicated treatment strategies. Fluoroquinolones have been the drugs of choice, but resistance to these is increasing, necessitating the use of third-generation cephalosporins or azithromycin.
With the rising trend of antibiotic resistance, the future lies in vaccine development. Current vaccines have limitations, but new-generation vaccines are under development. In addition, novel therapeutic strategies, such as the use of bacteriophages, are being explored.
Optimizing the diagnosis and treatment of enteric fever requires a multifaceted approach, encompassing the development of improved diagnostic tools, effective treatment regimens, and preventive measures. By staying abreast of emerging strategies, healthcare professionals can play a crucial role in managing this global health issue.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation